A Prospective Evaluation of BioMime™ - Sirolimus Eluting Coronary Stent in a Multi- Centre Study
Latest Information Update: 03 Jul 2019
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease
- Focus Adverse reactions
- Acronyms meriT-2
- Sponsors Meril Life Sciences
- 09 Apr 2018 Status changed from active, no longer recruiting to completed.
- 13 Dec 2016 New trial record